Stocktoria
Organon & Co. OGN
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2021-05-14
Organon & Co. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.2B | $6.4B | $6.3B | $6.2B | $6.3B |
| Gross profit | $3.3B | $3.7B | $3.7B | $3.9B | — |
| R&D expense | — | — | — | — | $443.0M |
| SG&A expense | $1.7B | $1.8B | $1.9B | $1.7B | $1.7B |
| Interest expense | $504.0M | $520.0M | $527.0M | $422.0M | $258.0M |
| Income tax | $238.0M | -$57.0M | -$350.0M | $205.0M | $178.0M |
| Net income | $187.0M | $864.0M | $1.0B | $917.0M | $1.4B |
| EPS (diluted) | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 |
| Operating cash flow | $700.0M | $939.0M | $799.0M | $858.0M | $2.2B |
| Free cash flow | $538.0M | $764.0M | $548.0M | $662.0M | $2.0B |
| Cash & equivalents | $574.0M | $675.0M | $693.0M | $706.0M | $737.0M |
| Inventory | $1.4B | $1.3B | $1.3B | $1.0B | $915.0M |
| Total assets | $12.9B | $13.1B | $12.1B | $11.0B | $10.7B |
| Total liabilities | $12.1B | $12.6B | $12.1B | $11.8B | — |
| Shareholders' equity | $752.0M | $472.0M | -$70.0M | -$892.0M | -$1.5B |
Source: SEC EDGAR filings · CIK 0001821825 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.